Phaseline

Companies › Unlimited Biotechnology

Unlimited Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV9-Follistatin gene therapy
Adeno-associated virus serotype 9 vector encoding human follistatin to increase muscle mas
FSTPhase 1Age-related Muscle DeclineSep 2027
VEGF Plasmid
Intramuscular plasmid DNA encoding vascular endothelial growth factor to induce angiogenes
VEGFAPhase 1Age-related Muscle DeclineSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07443826AAV9-Follistatin gene therapyPhase 1Age-related Muscle DeclineOtherSep 2027
NCT07443826VEGF PlasmidPhase 1Age-related Muscle DeclineOtherSep 2027

Targets

FST (1) VEGFA (1)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Biotheus AstraZeneca Prestige Biopharma Avirmax Biopharma Eli Lilly 4D Molecular Therapeutics PPD Development, LP

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.